In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Steven Kao, Medical Oncologist at Chris O'Brien Lifehouse, is joined by A/Prof Venessa Chin, Medical Oncologist at St Vincent's Hospital and Researcher at the Garvan Institute of Medical Research, and Dr Ben Kong, Medical Oncologist at Prince of Wales Hospital. Together, they explore the clinical features of ROS1-positive non-small cell lung cancer, the evolving diagnostic and treatment landscape in Australia, and how the recent PBS listing of repotrectinib is influencing first-line treatment decisions. The discussion also covers CNS disease, treatment sequencing, resistance mechanisms, and emerging therapies that may further improve outcomes for patients. This podcast was proudly sponsored by Bristol Myers Squibb. All development and editorial decisions were made independently by the speakers.
In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Steven Kao, Medical Oncologist at Chris O'Brien Lifehouse, is joined by A/Prof Venessa Chin, Medical Oncologist at St Vincent's Hospital and Researcher at the Garvan Institute of Medical Research, and Dr Ben Kong, Medical Oncologist at Prince of Wales Hospital. Together, they explore the clinical features of ROS1-positive non-small cell lung cancer, the evolving diagnostic and treatment landscape in Australia, and how the recent PBS listing of repotrectinib is influencing first-line treatment decisions. The discussion also covers CNS disease, treatment sequencing, resistance mechanisms, and emerging therapies that may further improve outcomes for patients.
This podcast was proudly sponsored by Bristol Myers Squibb. All development and editorial decisions were made independently by the speakers.
(00:00) Introduction, Host Welcome & Acknowledgement of Country
(01:33) The "Unicorn" Mutation: Clinical Characteristics & Prevalence
(03:22) Diagnostic Testing: IHC, FISH vs. Gold Standard NGS
(05:15) Clinical Red Flags: High Thromboembolic Risk & CNS Predilection
(08:18) Treatment Landscape in Australia: Crizotinib, Entrectinib, Repotrectinib
(10:11) Managing Unique Repotrectinib Side Effects (Dizziness, Dysgeusia, Ataxia)
(13:42) Intracranial Response & Choosing First-Line TKIs
(19:20) Post-TKI Progression Strategies: Biopsy, Chemo-IO, & Local Stereotactic Radiotherapy (SRS)
(26:15) The Horizon: Emerging Next-Generation TKIs & Resected ROS1 Disease
(29:05) Closing Remarks